HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2021

Jan 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2021-01-13

Reporting Person: Szekeres David Leslie (EVP, Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-13	Common Stock	M	1250	—	Acquired	1250	Direct
2021-01-13	Common Stock	F	423	$18.16	Disposed	827	Direct
2021-01-14	Common Stock	S	827	$18.0897	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-13	Restricted Stock Units	$	M	1250	Disposed		Common Stock (1250)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

F3: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of November 30, 2020.

F4: The range of sales prices received was $17.71 to $18.40. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.

F5: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020).